Anti‐neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity
ANCA+ IP patients had a high risk of developing SV and need close monitoring and prompt immunotherapy. ANCA+ IP patients not evolving to SV had a diagnosis of IIP or IPAF. These patients need longer observational studies to investigate if they represent a distinct ILD entity.
Authors
- Lisa Tescaro (ORCID: https://orcid.org/0009-0008-1990-7223)
- Davide Elia (ORCID: https://orcid.org/0000-0002-7440-4978)
- Antonella Caminati (ORCID: https://orcid.org/0000-0002-6414-3460)
- Francesca Luisi
- Matteo Colleoni (ORCID: https://orcid.org/0000-0002-4619-8062)
- Maria Rosa Mirenda
- Roberto Cassandro
- Roberto Felice Caporali (ORCID: https://orcid.org/0000-0001-9300-6169)
- Maria Rosa Pellico (ORCID: https://orcid.org/0009-0004-1921-7370)
- Sergio Harari (ORCID: https://orcid.org/0000-0001-8629-7391)
- Claudia Iannone (ORCID: https://orcid.org/0009-0005-5686-0127)
- Maurizio Zompatori
Institutions
- University of Milan (IT)
- MultiMedica (IT)
- Istituto Ortopedico Gaetano Pini (IT)
Publication Details
- Journal
- European Journal of Clinical Investigation
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1111/eci.70025
- Citations
- 2
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 3.04